scholarly journals P3.03-22 IL-1β as a New Early Predictive Biomarker for Non-Small Cell Lung Cancers Outcome

2018 ◽  
Vol 13 (10) ◽  
pp. S918
Author(s):  
S. Missiroli ◽  
N. Tamburini ◽  
M. Perrone ◽  
P. Maniscalco ◽  
R. Gafà ◽  
...  
PLoS ONE ◽  
2021 ◽  
Vol 16 (11) ◽  
pp. e0260500
Author(s):  
Tomoiki Aiba ◽  
Chieko Hattori ◽  
Jun Sugisaka ◽  
Hisashi Shimizu ◽  
Hirotaka Ono ◽  
...  

Although anti-PD-1/PD-L1 monotherapy has achieved clinical success in non-small cell lung cancer (NSCLC), definitive predictive biomarkers remain to be elucidated. In this study, we performed whole-transcriptome sequencing of pretreatment tumor tissue samples and pretreatment and on-treatment whole blood samples (WB) samples obtained from a clinically annotated cohort of NSCLC patients (n = 40) treated with nivolumab (anti-PD-1) monotherapy. Using a single-sample gene set enrichment scoring method, we found that the tumors of responders with lung adenocarcinoma (LUAD, n = 20) are inherently immunogenic to promote antitumor immunity, whereas those with lung squamous cell carcinoma (LUSC, n = 18) have a less immunosuppressive tumor microenvironment. These findings suggested that nivolumab may function as a molecular targeted agent in LUAD and as an immunomodulating agent in LUSC. In addition, our study explains why the reliability of PD-L1 expression on tumor cells as a predictive biomarker for the response to nivolumab monotherapy is quite different between LUAD and LUSC.


2020 ◽  
Author(s):  
Shahan Mamoor

Non-small cell lung adenocarcinoma (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the tyrosine kinase TEK in tumors from patients with NSCLC. TEK may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.


Author(s):  
Sajad Khan ◽  
Shahid Ali ◽  
Muhammad

Background:Lung cancers or (Bronchogenic-Carcinomas) are the disease in certain parts of the lungs in which irresistible multiplication of abnormal cells leads to the inception of a tumor. Lung cancers consisting of two substantial forms based on the microscopic appearance of tumor cells are: Non-Small-Cell-Lung-Cancer (NSCLC) (80 to 85%) and Small-Cell-Lung-Cancer (SCLC) (15 to 20%).Discussion:Lung cancers are existing luxuriantly across the globe and the most prominent cause of death in advanced countries (USA & UK). There are many causes of lung cancers in which the utmost imperative aspect is the cigarette smoking. During the early stage, there is no perspicuous sign/symptoms but later many symptoms emerge in the infected individual such as insomnia, headache, pain, loss of appetite, fatigue, coughing etc. Lung cancers can be diagnosed in many ways, such as history, physical examination, chest X-rays and biopsy. However, after the diagnosis and confirmation of lung carcinoma, various treatment approaches are existing for curing of cancer in different stages such as surgery, radiation therapy, chemotherapy, and immune therapy. Currently, novel techniques merged that revealed advancements in detection and curing of lung cancer in which mainly includes: microarray analysis, gene expression profiling.Conclusion:Consequently, the purpose of the current analysis is to specify and epitomize the novel literature pertaining to the development of cancerous cells in different parts of the lung, various preeminent approaches of prevention, efficient diagnostic procedure, and treatments along with novel technologies for inhibition of cancerous cell growth in advance stages.


2011 ◽  
Vol 10 (1) ◽  
pp. 26
Author(s):  
Nam Jin Yoo ◽  
Min Sung Kim ◽  
Sug Hyung Lee

FEBS Open Bio ◽  
2021 ◽  
Author(s):  
You‐Tyun Wang ◽  
Min‐Ru Lin ◽  
Wei‐Chen Chen ◽  
Wu‐Hsiung Wu ◽  
Feng‐Sheng Wang

Sign in / Sign up

Export Citation Format

Share Document